Novartis, INC.
​Multinational biopharmaceutical company.
Based in DC
🤖
AI Overview
With $1.7M in lobbying spend across 29 quarterly filings, Novartis, INC is a significant lobbying presence. Their lobbying covers 5 issue areas. Active from 2020 to 2025.
$1.7M
Total Spend
6
Years Active
1
Firms Hired
9
Lobbyists Deployed
5
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2020 | $190K |
| 2021 | $200K |
| 2022 | $650K |
| 2023 | $200K |
| 2024 | $200K |
| 2025 | $240K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Pharmacy, Health Issues, Medicare/Medicaid, Tariffs, Trade
- •Drug Pricing
- •COVID-19 Response.
- •COVID-19 Response.
- •Drug Pricing.
- •Drug Pricing.
- •Supply Chain.
Related Analysis
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
The 2025 Tariff Panic
As tariffs return, lobbying on trade surges.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Similar Clients
Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.)
$1.6M total spend
Sanofi U.S. Services, INC.
$1.6M total spend
Sanofi U.S. Services, INC.
$1.4M total spend
Teva Pharmaceuticals USA
$1.3M total spend
Association for Accessible Medicines (Formerly - Generic Pharmaceutical Assn)
$1.3M total spend
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.